



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 17-01-2011

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL
DESIGNS FOR THE WEEK-ENDING OF 01-01-2011 TO BE
PUBLISHED 19-01-2011 IN THE GAZETTE OF PAKISTAN PART-
V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

Sd/-

(Sabir Gul)

Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL: Eighteen pages.

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

27-12-2010

- 1087/2010 Nokia Siemens Networks OY., “Network Optimisation”
Finland
(Priority 08-01-2010 Europe)
- 1088/2010 Bayer CropScience AG., “Acaricidal and/or insecticidal active
Germany ingredient combinations”
(Priority 22-01-2010 Europe)

28-12-2010

- 1089/2010 Takeda San Diego, Inc., “A pharmaceutically acceptable salt of a
USA substituted 9h-pyrido[2,3-b]indoline”
(Priority 10-10-2006 USA)
Divisional
- 1090/2010 National Institute for “Characterization of cotton leaf curl
Biotechnology and Genetic kokhran virus C1 Rep promoter; a super
Engineering (NIBGE), strong promoter for high level gene
Faisalabad, expression in monocotyledonous and
Pakistan dicotyledonous crops”

29-12-2010

- 1091/2010 Itt Water & Wastewater “Apparatus and method for securing
Leopold, Inc., underdrain filter block”
USA
(Priority 18-01-2010 USA)
- 30-12-2010
- 1092/2010 Otsuka Pharmaceutical Co., “Therapeutic compounds and related
Ltd., methods of use”
Japan
Galenea Corporation,
USA
(Priority 31-12-2009 USA)
- 1093/2010 Dr. Nazre Haider & M Maaz “SECRET”
Khan,
(DESTO),
Rawalpindi,

1094/2010 Pakistan
Dr. Nazre Haider & M Maaz
Khan,
(DESTO),
Rawalpindi,
Pakistan

“SECRET”

01-01-2011

01/2011 Regeneron Pharmaceuticals,
Inc.,
USA
(Priority 08-01-2010 USA)

“Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

984/2003 Millennium Pharmaceuticals Inc., USA “(S)-5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-prop-ylidene}-5,11-dihydro-10-oxa-1-aza dibenzo[a,d] cycloheptene-7-carboxylic acid”

CO7D 491/04

141070

The invention provides compound having the formula:



wherein R¹ is halogen. The invention also provides composition comprising the compound. The disclosed compound have CCR1 antagonist activity.


245/2006 Bayer Cropscience AG., “Spiroketal-substituted cyclic ketoenol”

Germany

AOIN 43/08

141071

The invention relates to novel spiroketal-substituted cyclic ketoenol of the formula (I)



in which

A, B, Q¹, Q², D, G, W, X, Y and Z are as defined above.

to process and intermediate for its preparation.

Moreover, the invention relates to selective herbicidal composition comprising, firstly, spiroketal-substituted cyclic ketoenol and, secondly, a crop plant compatibility-improving compound.


15/2007
Millinnium Pharmaceuticals
Inc.,
USA

“Salt of (S)-5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-prop-ylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cycloheptene-7-carboxylic acid”

CO7D 491/04

141072

The invention provides a physiological salt of compound having the formula:



wherein R¹ is halogen. The invention also

provides composition comprising the compound, and method of treating diseases or disorders that comprise administering one or more of the compound to a subject in need thereof. The disclosed compound have CCR₁ antagonist activity.

23/2007 Novartis AG.,
Switzerland

“A composition comprising an antigen-binding region for Antibodies of dickkopf (dkk1)”.

A61P 19/08, A61P 35/04, A61K 39/395

141073

Antibodies and fragments that bind to the protein target Dickkopf (DKKI) are provided, for treating a target cell, in particular, a cell associated with an osteolytic condition. More specifically, disclosed is a composition comprising an antigen-binding region that specifically binds an epitope in a DKK1 polypeptide (SEQ ID NO: 1) and/or in a DKK4 polypeptide (SEQ ID: 124), wherein the antibody or functional fragment thereof binds to at least one epitope in DKKI or DKK4, or both.

251/2007 Polyethylene Technologies
Limited,
Great Britain

"Uv resistant multilayered cellular confinement system"

C08L 21/00, B29B 13/00

141074

The present disclosure generally relates to a polymeric cellular confinement system which can be filled with soil, concrete, aggregate, earth materials, and the like. More specifically, the present disclosure concerns a cellular confinement system characterized by improved durability against damage generated by UV light, humidity, and aggressive soils, or combinations thereof.


512/2007 University College Cardiff
Consultants Limited,
Katholieke Universiteit
leuven,
Belgium

“Substituted ester compound of nucleoside
analogue”

CO7D 491/04, CO7H 19/04

141075

A compound having the general formula
(II):




wherein X is O, S, NH or CH₂,

Y is O, S or NH,

Z is O, S or CH₂,

R₁ is C₁₋₆ alkyl, preferably n-alkyl, e.g., *n*-
pentyl or n-hexyl, and

one of R₂ and R₃ is OH, and the other of R₃
and R₂ is a neutral, non-polar amino acid
moiety. Said neutral, non-polar amino acid
moiety R₂ or R₃ may be:



in which R₄, R₅, R₆ and R₇ are each
independently H or C₁₋₂ alkyl. In preferred
embodiments, one of R₂ or R₃ is valine,
leucine, isoleucine or alanine, particularly
valine.


1397/2007 AustraZeneca AB.,
Sweden

“2-Alkylurea-4-aryl-5-cycllyl-pyridine and
2-alkylurea-4-aryl-5-cycllyl-pyrimidine”
Compound

CO7D 213/75, CO7D 239/42, A61K
31/427, A61P 31/04 CO7D 417/04

141076

Compound is described



244/2008 Omya Development AG.,
Switzerland

“Process for the removal of endocrine
disrupting compound from an aqueous
medium”

BO1J 20/04, CO2F 1/28, CO9C 1/02, CO2F
101/30

141077

The present invention relates to the removal of endocrine disrupting compound from an aqueous medium by adding surface-reacted natural calcium carbonate or an aqueous suspension comprising surface-reacted calcium carbonate and having a pH greater than 6.0 measured at 20 °C, to the medium, wherein the surface-reacted calcium carbonate is a reaction product of natural calcium carbonate with carbon dioxide and one or more acids, the use of the surface-reacted natural calcium carbonate for the removal of endocrine disrupting compounds, as well as to a combination of a surface-reacted natural calcium carbonate and activated carbon for the removal of endocrine disrupting compounds.


399/2008 Sanofi-Aventis,
France

“Substituted triazolo[4,5-b]pyridin-3-yl]-[4-
(3- trifluoromethylphenyl)-piperazin-1-
yl]methanone compound”

CO7D 471/04, CO7D 487/04, A61K
31/4439, A61P 31/00

141078

The invention relates to a compound of the general formula (I)



in which:

A and X represent, independently of one another, a nitrogen atom or a CH group;

R₁ represents an aryl or heteroaryl group, optionally substituted by one or more groups chosen from a halogen atom, a (C₁-C₆)alkyl, halo(C₁-C₆)alkyl, (C₁-C₆)alkoxy or halo(C₁-C₆)alkoxy group; and

R₂ represents an aryl group, optionally substituted by one or more groups chosen from a halogen atom, a methyl, trifluoromethyl, methoxy or trifluoromethoxy group,

preparation method and pharmaceutical composition comprising thereof.

678/2008 BASF SE.,
Germany

“A process for manufacturing pesticide treated fabric and/or Melting materials by impregnating said nettings with an Aqueous composition comprising a pesticide and a polymeric Binder”

DO6M 15/227, DO6M 15/263, DO6M 16/00, CO9D 123/08, AO1N 25/02

141079

A composition for the impregnation of non-living-materials, preferably textile materials, comprising at least a pesticide and a polymeric binder comprising as monomers at least ethylene and an

unsaturated carboxylic acid, process for impregnating such materials and the use of such impregnated materials as mosquito-nets and for the protection of plants and other goods.


05/2009 Sanofi-Aventis,
France

“2-heteroarylimidazo[1,2-a]pyridine compound”

CO7D 471/04, CO7D 5/04, A61K 31/437,
A61P 25/00

141080

Compound of formula (I):



in which:

X represents a benzodioxole group or a heteroaromatic group, linked via a carbon atom, R₂ represents a hydrogen atom, a halogen atom, a group (C₁-C₆)alkyl, a group (C₁-C₆)alkoxy, a group (C₁-C₆)alkylthio, a group (C₂-C₆)alkenyl, a group (C₂-C₆)alkynyl, a group —CO-R₅, a group —CO—NR₆R₇, a group —CO—O—R₈, a group —NR₉—CO—R₁₀, a group —NR₁₁R₁₂, a cyano group, a phenyl group or a heterocyclic group,

R₁ represents a hydrogen atom, a halogen, a group (C₁-C₆)alkoxy, a group (C₁-C₆)alkyl, a hydroxyl or an amino,

R₃ represents a hydrogen atom, a group (C₁-C₆)alkyl, a halogen atom or a hydroxyl group,

R₄ represents a hydrogen atom or a halogen atom, and pharmaceutical composition comprising thereof.

251/2009 Sanofi-Aventis,

“polysubstituted


2-aryl-6-

France

phenylimidazo[1,2-a]pyridine compound”
CO7D 213/28, CO7D 233/56, CO7D
471/04, A61K 31/437, A61P 19/00, A61P
25/00, A61P 35/00

141081

Compound of formula (1):



in which:

R₁ represents: a phenyl group or a naphthyl group, it being possible for these two groups to be optionally substituted; X represents from 1 to 4 substituents, which are identical to or different from one another, chosen from hydrogen, halogen, (C₁-C₁₀)alkyl, halo(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxy, NRaRb, cyano, nitro; R represents, at position 3, 5, 7 or 8 of the imidazo[1,2-a]pyridine, from 1 to 4 substituents, which are identical to or different from one another; R₂ and R₃ represent, independently of one another, a hydrogen atom or an optionally substituted (C₁-C₁₀)alkyl group; an optionally substituted aryl group; R₂ and X may form, together with the carbon atoms which bear them, a carbon-based ring containing from 5 to 7 carbon atoms; R₄ represents: a hydrogen atom, an optionally substituted (C₁-C₁₀)alkyl group, or an aryl group optionally substituted with one or more substituents, Pharmaceutical composition comprising thereof and process for the synthesis thereof.

364/2009 SmithKline Beecham
Corporation,
USA


“A pharmaceutical composition comprising N¹ {3-fluoro-4-[(6-(methyloxy)-7- [[3-(4-morpholinyl)propyl]oxy)-4-Quinolinyloxy]phenyl)- N¹-(4-fluorophenyl)-1,1-Cyclopropanedicarboxamide”

CO7D 413/00, CO7D 401/00

141082

The present invention relates to a pharmaceutical composition for treating cancer in a patient comprising:

a) a compound of formula A:



or a pharmaceutically acceptable salt thereof, wherein R¹-R⁴, p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof wherein the compound of formula A and the erbB inhibitor have a synergistic effect in inhibiting cell growth compared with the compound of formula A and the erbB inhibitor alone. The pharmaceutical composition of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.

642/2009 Bayer Schering Pharma
Aktiengesellschaft,
Germany

“Estratriene compound comprising heterocyclic bioisostere for the phenolic A-ring”

CO7J 71/00, A61K 31/58 A61P 5/30

141083

The present invention is directed to novel pyrazolo-estrien and triazolo-estrien compound pharmaceutical composition containing them and its use in the treatment or prevention of disorders and diseases mediated by an estrogen receptor such as

hot flashes, vaginal dryness, osteopenia, osteoporosis, hyperlipidemia, loss of cognitive function, degenerative brain diseases, cardiovascular diseases, cerebrovascular diseases, hormone sensitive cancers and hyperplasia (in tissues including breast, endometrium, and cervix in women and prostate in men), endometriosis, uterine fibroids, osteoarthritis; and as contraceptive agents either alone or in combination with a progestogen or progestogen antagonist. The compound: of the invention is selective estrogen receptor modulators.


989/2010 AstraZeneca AB.,
Sweden

“A Pharmaceutically acceptable salt of 2-Alkylurea-4-aryl-5-cyclyl-pyridine and 2-alkylurea-4-aryl-5-cyclyl-pyrimidine Compound”

CO7D 417/04, CO7D 213/75, CO7D 239/42, A61K 31/427, A61P 31/04

141084

A pharmaceutically acceptable salt of compound of formula (XVIII):



wherein:

X is CH or N; and

R²⁹ is a 6-membered aryl or a 5- or 6-membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted on one or more carbon atom with one or more R¹¹; and wherein if the heteroaryl comprises a -NH- moiety the hydrogen may be optionally substituted with a group selected from R⁸;

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl or C₃₋₆cycloalkyl; wherein R¹ may be optionally substituted on carbon by one or more R⁶;

Ring B is carbocyclyl or heterocyclyl;

wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁴;

R⁵ is selected from hydroxy, C₁₋₆alkoxy, -N(R¹⁵)(R¹⁶) and a nitrogen linked heterocyclyl; wherein said C₁₋₆alkoxy may be optionally substituted on carbon by one or more R¹⁷; and wherein if said nitrogen linked heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁸;

R⁶, R¹¹ and R¹⁷ are substituents on carbon and are each independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₇₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)2amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)2carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, C₁₋₆alkoxycarbonylamino, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)2sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶, R⁷, R¹¹ and R¹⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R¹⁵ and R¹⁶ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, carbocyclyl or heterocyclyl; wherein R¹⁵ and R¹⁶ independently of each other may be optionally substituted on carbon by one or more R²¹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²²;

R⁸, R¹⁴, R¹⁸, R²⁰ and R²² are independently selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl,

benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁸, R¹², R¹³, R¹⁴, R¹⁸, R²⁰ and R²² independently of each other may be optionally substituted on carbon by one or more R²³; and R¹⁹, R²¹ and R²³ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl.

CEASED CASES

The following patents have been ceased due to non payment of renewal fee

File No.	Reg.No.	Title	Representative	Applicant
010/1996	134989	ELECTRICAL APPARATUS FOR CONVERTING THE SUPPLY VOLTAGE OF A D.C.POWER SUPPLY.	Bharucha & Co., 214-216 Commerce Center Hasrat Mohani Road. P.O.Box No.411. Karachi.Pakistan.	Autotronics Engineering International Limited
31/1996	135003	A WIRELESS SYSTEM OF TRANSMITTING AND RECEIVING AUDIO FREQUENCY OF TV.	Abid T.Japanwalla, Finlay House 4th Floor, I.I.Chundrigar Road. Karachi.Pakistan.	Messrs Orion Electronics Private Limited
008/1997	135634	PROCESS FOR THE PREPARATION OF NOVEL SUBSTITUTED IMIDAZOL COMPOUNDS	United Trademark & Patent Services, West End Building,61- The Mall, Lahore.Pakistan.	Smithkline Beecham Corporation.
204/19970	135642	PROCESS FOR THE PREPARATION OF NEW SUBSTITUTED {2-C1PIPERDZINYL ETHOXY METHYL COMPOUNDS	United Trademark & Patent Services, West End Building,61- The Mall, Lahore.Pakistan.	UCB Pharma S.A.
007/1998	136226	DRY FILM COATING COMPOSITION CONTAINING A DEXTRIN AND A DETACKIFIER	Vellani & Vellani , 148, 18th East Street, Phase 1, Defence Officers' Housing Authority, Karachi-75500 (Pakistan)	Berwind Pharmaceutica Services,Inc.l

84/2002	138096	MARKER PENS	Chughtai M.Jamiluddin, State Life Building No.1-B I.I.Chundrigar Road. Karachi.Pakistan.	Bolton terrence William
120/2003	138456	THERAPEUTIC HETROCYCLIC COMPOUND COMPRISING PIPERAZIN	Surridge and beecheno. 3rd Floor Finaly House, I.I.Chundrigar Road, Karachi.(Pakistan).	Astra zeneca AB
121/2003	138457	THERAPEUTIC CHROMONE COMPOUND	Surridge and beecheno. 3rd Floor Finaly House, I.I.Chundrigar Road, Karachi.(Pakistan)	Astra zeneca AB
74/2004	138748	AUTO THERMAL TRACKING REACTOR	Khurshed khan and Associates, 305 Amber estate, K.C.H.S. Block 7 and 8, Shahreh-e-Faisal Karachi.Pakistan.	BP Chemicals Limited
79/2004	138818	HYDRO-GRAVITY POWER PLANT	Major Rashid Iqbal Ansari, 602 Combined Workshop EME Karachi Cantt.Pakistan.	Major Rashid Iqbal Ansari
88/2004	138822	A PROCESS FOR PREPARING A SYANO-SUBTITUTED QUINOLINE COMPOUND AS WELL AS ITS INTERMEDIATE PRODUCTS	Remfry and Son, 305-308, Al Ameera Center , Shahrah-e-Iraq.Saddar Karachi Pakistan.	Avanir Pharmaceuticals
102/2004	138825	IMPROVMENTS IN OR RELATING TO AN ACCESSORY FOR A FEUL BURNING OR PROCESSING ENGINE OR MACHINE .	Vellani & Vellani , 148, 18th East Street, Phase 1, Defence Officers' Housing Authority, Karachi-75500 (Pakistan)	I Law Seng Teck,Malaysia

33/2005	139179	A LIQUID COMPOSITION COMPRISING A REACTIVE DYE AND ALKALI METAL POLYACRYLATES OR METHACRYLATES FOR USE IN A DYEING OR PRINTING.	Bharucha & Co., 214-216 Commerce Center Hasrat Mohani Road. P.O.Box No.411. Karachi.Pakistan.	Clariant International Limited.
1213/2001	139390	ARY/CYCLOALKYL-CABOXYLIC ACID	United Trademark & Patent Services, West End Building,61-The Mall, Lahore.Pakistan.	Daiichi Sankayo Co.Ltd.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>27-12-2010</u>			
1)	15099	Gloves (Class-)	Mountain Hardwear, Inc.
<u>30-12-2010</u>			
2)	15100	Motor Bike Shoes (Class-10)	Sigma Shoes (Pvt.) Ltd
<u>01-01-2011</u>			
3)	15101	Packaging (Class-05)	Gujranwala Food Industries (Pvt.) Ltd

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Inventor
<u>30-12-2010</u>			
a)	15027	Package (Class-05)	Tetra Laval Holdings & Finance S.A
b)	15028	Package (Class-05)	Tetra Laval Holdings & Finance S.A
c)	15029	Package (Class-05)	Tetra Laval Holdings & Finance S.A

Sd/-

(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056